Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James J. Devlin is active.

Publication


Featured researches published by James J. Devlin.


Drug Development Research | 1996

High capacity screening of pooled compounds: Identification of the active compound without re‐assay of pool members

James J. Devlin; Amy Liang; Lan Trinh; Mark A. Polokoff; David Senator; Wei Zheng; Jason Kondracki; Peter J. Kretschmer; John Morser; Samuel E. Lipson; Richard Spann; John Loughlin; Kathryn V. Dunn; Michael M. Morrissey

A matrix‐based compound pooling and deconvolution method has been developed that significantly increased the efficiency of a high‐capacity screening program. This method is based on screening pools of 10 compounds. The matrix used to assemble the pools resulted in each compound being assayed twice—each time with a completely different set of pooled compounds. The active compound in an active pool was accurately predicted by determining which compound was present in an active pool both times that a pool containing that compound was tested. This has eliminated the need to re‐assay each individual member of active pools. This approach has been tested with a set of 6,680 compounds in three different assays: inhibition of Factor Xa, inhibition of gastrin‐releasing peptide receptor binding, and inhibition of nitric oxide synthase (isoform II). Thus significant time is saved not only by pooling the compounds for the initial assay but also by avoiding the need to re‐assay all compounds in active pools. Moreover, no false negatives occurred in these assays—an important consideration from a drug discovery perspective.


Proceedings of the National Academy of Sciences of the United States of America | 2000

Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry

Kirk McMillan; Marc Adler; Douglas S. Auld; John J. Baldwin; Eric Blasko; Leslie J. Browne; Daniel Chelsky; David D. Davey; Ronald E. Dolle; Keith A. Eagen; Shawn D. Erickson; Richard I. Feldman; Charles B. Glaser; Cornell Mallari; Michael M. Morrissey; Michael Ohlmeyer; Gonghua Pan; John Parkinson; Gary Phillips; Mark Polokoff; Nolan H. Sigal; Ronald Vergona; Marc Whitlow; Tish A. Young; James J. Devlin


Archive | 1991

Compositions and methods for identifying biologically active molecules

James J. Devlin


Journal of Medicinal Chemistry | 2007

Design, Synthesis, and Activity of 2-Imidazol-1-ylpyrimidine Derived Inducible Nitric Oxide Synthase Dimerization Inhibitors

David D. Davey; Marc Adler; Damian O. Arnaiz; Keith Eagen; Shawn D. Erickson; William J. Guilford; Margaret Kenrick; Michael M. Morrissey; Mike Ohlmeyer; Gonghua Pan; Vidyadhar Paradkar; John A. Parkinson; Mark A. Polokoff; Kurt W. Saionz; Cecile Santos; Babu Subramanyam; Ron Vergona; Robert G. Wei; Marc Whitlow; Bin Ye; Zuchun Zhao; James J. Devlin; Gary Phillips


Drug Development Research | 1994

Scanning whole cells with phage-display libraries : identification of peptide ligands that modulate cell function

Susan Fong; Laura V. Doyle; James J. Devlin; Michael V. Doyle


Archive | 1992

Peptide inhibitors of platelet adhesion

James J. Devlin; Michael V. Doyle; Susan Fong


Archive | 1991

Recombinant colony stimulating factor-1 for treatment of fungal infection

Peter Ralph; Kong T. Chong; James J. Devlin; Robert Zimmerman; Sharon Lea Aukerman; David B. Ring; Sylvia Ma


Archive | 1995

Use of CSF-1 to treat tumor burden

Peter Ralph; Kong T. Chong; James J. Devlin; Robert Zimmerman; Sharon Lea Aukerman; David B. Ring; Sylvia Ma


Archive | 2000

N-heterocyclische derivate als nos inhibitoren N-heterocyclic derivatives as inhibitors nos

O. Damian Arnaiz; John J. Baldwin; D. David Davey; James J. Devlin; Ellwood Roland Dolle; David Shawn Erickson; Kirk McMillan; Michael M. Morrissey; H. Michael Ohlmeyer; Gonghua Pan; Madhav Vidyadhar Paradkar; John Parkinson; B. Gary Phillips; Bin Ye; Zuchun Zhao


Archive | 1998

Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase

Damian O. Arnaiz; John J. Baldwin; David D. Davey; James J. Devlin; Roland E. Dolle; Shawn D. Erickson; Kirk McMillan; Michael M. Morrissey; Michael Ohlmeyer; Gonghua Pan; Vidyadhar M. Paradkar; John Parkinson; Gary Phillips; Bin Ye; Zuchun Zhao

Collaboration


Dive into the James J. Devlin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bin Ye

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

David D. Davey

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kirk McMillan

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge